Nihon Servier

Nihon Servier is the Japanese subsidiary of the Servier Group, an independent international pharmaceutical company governed by a non-profit foundation. Established in 1991 and headquartered in Tokyo, the company focuses on bringing Servier's global innovations to the Japanese market, with a primary emphasis on oncology, cardiovascular diseases, and neuroscience. Nihon Servier manages clinical development, regulatory affairs, and commercial operations within Japan, often collaborating with local partners like Yakult Honsha to enhance patient access. The company's current portfolio and pipeline highlight targeted therapies for hard-to-treat cancers, including IDH-mutant malignancies and pancreatic cancer. By leveraging the parent group's significant investment in R&D, Nihon Servier aims to address high unmet medical needs in the Japanese healthcare landscape.